Phase 3 Readout
NMRA: Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep
June 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2027
- Company
- Neumora Therapeutics, Inc. (NMRA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep
- Indication
- Major Depressive Disorder